Trials / Terminated
TerminatedNCT01264341
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Phase II Study of Efficacy and Safety of Bevacizumab in Combination With Temsirolimus, After 1st Line Anti-VEGF Treatment in Patients With Advanced Renal Cancer
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Hellenic Cooperative Oncology Group · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether the combination of bevacizumab/temsirolimus is effective in patients with advanced renal carcinoma progressing after anti-VEGF treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bevacizumab | Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal. |
| DRUG | Temsirolimus | Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal. |
Timeline
- Start date
- 2010-12-01
- Primary completion
- 2015-07-01
- Completion
- 2015-07-01
- First posted
- 2010-12-21
- Last updated
- 2017-02-14
Locations
8 sites across 1 country: Greece
Source: ClinicalTrials.gov record NCT01264341. Inclusion in this directory is not an endorsement.